New Advances in Radioimmunotherapy for the Treatment of Cancers
Radionuclide T 1/2 (h)a Emissionsb Emax (keV)c Range max in soft tissue (mm)c Usual labeling method Technetium-99 m 6.0 γ 140 Direct labeling or N2S2 or N3S complexes Indium-111 67…
Toll-Like Receptor Pathway and its Targeting in Treatment of Cancers
Cancer type TLRs expressed Basal cell carcinoma TLR7 Breast cancer TLR2, 3, 4, 5, 7, and 9 Brain cancer TLR2 and 4 Colorectal cancer TLR2, 3, 4, 5, 7, and…
B Cell Regulation of Antitumor Response
Fig. 15.1 Tumor growth, CTL activity, IFN-γ expression; a comparison in B cell-depleted mice (BCDM), B cell-reconstituted BCDM, and immunocompetent wild-type (WT) mice. Mice were subcutaneously injected with 106 EMT-6…
Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotherapy
Fig. 14.1 Schematic representation of adoptive T cell transfer therapy using T cells genetically modified with chemokine receptor. Tumor mass is excised from the patient and TILs (tumor-infiltrating lymphocytes) are…
Frontiers in Cancer Immunotherapy
Type Application Target Alemtuzumab Chronic lymphocytic leukemia CD52 Bevacizumab Anti-angiogenic therapy Vascular endothelial growth factor (VEGF) Cetuximab Colorectal, head, and neck cancer Epidermal growth factor receptor (EGFR) Gemtuzumab Acute myeloid…
Ethical Considerations in Cancer Immunotherapy
1 Unique toxicities 2 Evaluation of efficacy in clinical trials and non-research settings 3 Ethical justification for initiation of treatment in individual patients 27.3 Unique Toxicities The side effects of…
Psychoneuroendocrinoimmunotherapy of Cancer
© Springer-Verlag Berlin Heidelberg 2015Nima Rezaei (ed.)Cancer Immunology10.1007/978-3-662-44946-2_26 26. Psychoneuroendocrinoimmunotherapy of Cancer Paolo Lissoni1 , Giusy Messina1 and Franco Rovelli1 (1) Italian Association of Integrative Medicine (AIMI), Milan, 21124, Italy Paolo Lissoni (Corresponding author) Email: p.lissoni@hsgerardo.org Giusy Messina…
Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy
Fig. 24.1 This is a proposed schema for intensive immune monitoring. Flow cytometry can be performed on peripheral blood to analyze multiple parameters for T cell activation/exhaustion markers, regulatory T…
Tumor-Associated Macrophages and Cancer Development
Fig. 20.1 Two mechanisms proposed to explain the association between TAMs and tumorigenesis. (a) A large set of chemokines (CCL2 and others) and cytokines (G-CSF and so on) secreted by…
Dendritic Cell Vaccines for Cancer Therapy: Fundamentals and Clinical Trials
22. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711.PubMed 23. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, et al. Rapid…
